Organon & Co. (OGN) To Go Ex-Dividend on November 9th

Organon & Co. (NYSE:OGN) declared a quarterly dividend on Friday, October 30th. Stockholders of record on Monday, November 9th will be given a dividend of $0.02 per share on Thursday, December 10th. This represents a $0.08 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend is Monday, November 9th.

Organon & Co. has a payout ratio of 2.0% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Organon & Co. to earn $3.43 per share next year, which means the company should continue to be able to cover its $0.08 annual dividend with an expected future payout ratio of 2.3%.

Organon & Co. Stock Performance

Organon & Co. stock opened at $13.84 on Friday. The business’s 50-day moving average price is $13.75 and its two-hundred day moving average price is $11.60. The stock has a market cap of $3.63 billion, a PE ratio of 18.20, a P/E/G ratio of 1.27 and a beta of 1.53. Organon & Co. has a 12-month low of $5.69 and a 12-month high of $13.88. The company has a quick ratio of 1.44, a current ratio of 2.02 and a debt-to-equity ratio of 7.11.

Organon & Co. (NYSE:OGN) last posted its earnings results on Friday, October 30th. The company reported $0.94 earnings per share for the quarter, beating analysts’ consensus estimates of $0.88 by $0.06. Organon & Co. had a return on equity of 82.06% and a net margin of 3.49%. The company had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.58 billion. As a group, analysts expect that Organon & Co. will post 3.24 earnings per share for the current fiscal year.

Organon & Co. Company Profile

Organon & Co is a global health care company focused on improving the health and quality of life of women throughout their lives. The company develops, manufactures and commercializes prescription medicines and other health care products, with operations serving patients and health care providers in markets around the world.

Organon’s women’s health portfolio includes contraceptive products such as Nexplanon and NuvaRing, as well as medicines and technologies related to fertility, pregnancy and other reproductive health needs.